{
    "clinical_study": {
        "@rank": "122619", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "Local use of rhGM-CSF + Compound Vitamin B12 solution: The rhGM-CSF is prepared as a mouthwash solution,diluting 150\u03bcg in 100ml water(final concentration of 1.5\u03bcg/ml).Patient is instructed to use the solution five times daily.\nCompound Vitamin B12 solution 5ml being sprayed to mouth five times daily\nRadiotherapy: Intensity modulated radiation therapy(IMRT)\nChemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy."
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Active Comparator", 
                "description": "Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily\nRadiotherapy: Intensity modulated radiation therapy(IMRT)\nChemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a open,randomized  phase II trial comparing effectiveness and safety of local use of\n      rhGM-CSF and Compound Vitamin B12 to Compound Vitamin B12 solution alone treating oral\n      mucositis in primary nasopharyngeal cancer. The main end point is the incidence of grade II\n      and less oral mucositis at the end of treatment.The hypothesis of the study is that the\n      local use of rhGM-CSF and Compound Vitamin B12 can decrease the incidence of grade III and\n      more oral mucositis at the end of treatment compared to local use of Compound Vitamin B12\n      alone."
        }, 
        "brief_title": "Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Nasopharyngeal Cancers", 
        "condition_browse": {
            "mesh_term": [
                "Stomatitis", 
                "Nasopharyngeal Neoplasms", 
                "Mucositis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Inclusion Criteria:\n\n        1. Grade II oral mucositis induced by chemoradiotherapy in patient with primary\n           nasopharyngeal carcinoma.\n\n        2. Receiving 68-72 Gray of radiation dose.\n\n        3. Age between 18 and 65 years.\n\n        4. KPS\u226570.\n\n        5. Patient who has given his/her written consent before any specific procedure of the\n           protocol.\n\n      Exclusion Criteria:\n\n        1. Severe uncontrolled infection.\n\n        2. Pregnant or breast-feeding females.\n\n        3. Allergy to this medicine.\n\n        4. Diarrhea.\n\n      Outcome measures:\n\n        1. Grade of oral mucositis:NCI Common Terminology Criteria for Adverse Events v3.0, NCI\n           CTCAE v3.0\n\n        2. Pain: WHO,Numerical Rating Scale(NRS)\n\n        3. Tumor response to chemoradiotherapy:Response Evaluation Criteria in Solid\n           Tumors,RECIST1.1"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Grade II oral mucositis induced by chemoradiotherapy in patient with primary\n             nasopharyngeal carcinoma.\n\n          2. Receiving 68-72 Gray of radiation dose.\n\n          3. Age between 18 and 65 years.\n\n          4. KPS\u226570.\n\n          5. Patient who has given his/her written consent before any specific procedure of the\n             protocol.\n\n        Exclusion Criteria:\n\n          1. Severe uncontrolled infection.\n\n          2. Pregnant or breast-feeding females.\n\n          3. Allergy to this medicine.\n\n          4. Diarrhea."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01806272", 
            "org_study_id": "L-12-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A", 
                "description": "The rhGM-CSF is prepared as a mouthwash solution,diluting 150\u03bcg in 100ml water(final concentration of 1.5\u03bcg/ml).Patient is instructed to use the solution five times daily.", 
                "intervention_name": "rhGM-CSF", 
                "intervention_type": "Drug", 
                "other_name": "\u7279\u5c14\u7acb"
            }, 
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B"
                ], 
                "description": "Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily", 
                "intervention_name": "Compound Vitamin B12", 
                "intervention_type": "Drug", 
                "other_name": "\u8d2f\u65b0\u514b"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin B 12", 
                "Hydroxocobalamin", 
                "Vitamin B Complex", 
                "Vitamins", 
                "Molgramostim"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "rhGM-CSF", 
            "Oral Mucositis", 
            "Primary Nasopharyngeal Cancers", 
            "Chemoradiotherapy"
        ], 
        "lastchanged_date": "March 27, 2013", 
        "location": {
            "contact": {
                "email": "luowei2@mail.sysu.edu.cn", 
                "last_name": "Wei LUO, M.D.", 
                "phone": "+862087343483"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "Sun Yat-sen University Cancer Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Open,Randomized Phase II Trial Comparing Local Use of rhGM-CSF and Compound Vitamin B12 Solution to Compound Vitamin B12 Solution Alone Treating Chemoradiotherapy-induced Oral Mucositis in Patients With Primary Nasopharyngeal Carcinoma", 
        "overall_contact": {
            "email": "luowei2@mail.sysu.edu.cn", 
            "last_name": "Wei LUO, M.D.", 
            "phone": "+862087343483"
        }, 
        "overall_official": {
            "affiliation": "Sun Yat-sen University", 
            "last_name": "Wei LUO, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Using the criteria of NCI CTCAE v3.0", 
            "measure": "The incidence of grade II and less oral mucositis at the end of treatment", 
            "safety_issue": "Yes", 
            "time_frame": "7 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01806272"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Wei LUO", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Cumulative incidence and time of different grade,using the criteria of WHO,NRS", 
                "measure": "Pain", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Using the criteria of NCI CTCAE v3.0", 
                "measure": "Cumulative incidence and time of grade III and more oral mucositis", 
                "safety_issue": "Yes", 
                "time_frame": "7 weeks"
            }, 
            {
                "description": "Cumulative incidence and time of different grade,using NCI CTCAE v3.0", 
                "measure": "Dysphagia", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Using the criteria of Response Evaluation Criteria in Solid Tumors1.1(RECIST1.1)", 
                "measure": "Tumor response to chemoradiotherapy", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wei LUO", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}